In a report released today, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on Marinus (NASDAQ: MRNS), with a price target of $19. The company’s shares opened today at $6.09.
Piros said:
“Given the compelling Phase 2 data announced in CDD, market size potential in PPD, and undervaluation relative to peers, we believe Marinus shares offer a compelling risk- reward profile. The company has three important data read-outs remaining in 4Q18, which we believe could become significant catalysts for the shares. Valuation Summary We arrive at our 12-month PT of $19/share by assessing the after-tax, risk-adjusted NPV of potential future cash flows from ganaxolone for the treatment of postpartum depression and CDKL5 deficiency disorder.”
According to TipRanks.com, Piros is ranked 0 out of 5 stars with an average return of -7.0% and a 40.2% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.
Currently, the analyst consensus on Marinus is a Strong Buy with an average price target of $16.75, representing a 175.0% upside. In a report issued on July 19, Mizuho Securities also maintained a Buy rating on the stock with a $13 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.87 and a one-year low of $1.80. Currently, Marinus has an average volume of 746.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.
